Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03485547
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03485547 ↗
- Completed
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on NCT03485547 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03485547 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Venetoclax
- Arms
- Venetoclax · Experimental
- Enrollment
- 5
- Primary outcomes
- Dose Limiting Toxicity
- Sponsor
- Dana-Farber Cancer Institute with AbbVie
- Start
- Aug 23, 2018
- Primary completion
- Jan 10, 2022
- Results posted
- No
- Registry record
- NCT03485547 · updated Feb 2, 2026
Publications
linked from the registry- Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. No abstract available. PubMed 33795208